Fluoroquinolone Resistance Prevalence Study

Stopped early

Conditions studied: Multiple Myeloma

In brief

This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.

Key facts

Study ID

NCT05824689

Run by

Hackensack Meridian Health

People needed

124

Starts

2022-07-08

Expected to finish

2025-01-15

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects >18 yrs of age.
• Diagnosis of multiple myeloma undergoing (first or subsequent) autologous PBSC transplantation.
• Transplant conditioning with melphalan 200 mg/m2.
• PBSC cell dose of >2x10e6 CD34+ cells/kg.
• Able to receive fluoroquinolone prophylaxis.
• Subjects must give consent for enrollment into this study.

You may not qualify if…

• Unwillingness to provide informed consent.
• Enrollment into a treatment protocol prescribing antibiotic prophylaxis.
• A diagnosis other than multiple myeloma.
• Receiving a conditioning regimen other than melphalan 200 mg/m2.
• Known light-chain amyloid deposition in any organ.

Where it is running

• Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia, United States
• John Theurer Cancer Center, Hackensack Meridian Health — Hackensack, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.